Singapore markets open in 38 minutes
Straits Times Index
3,304.99 +15.57 (+0.47%) S&P 500
5,297.10 -11.05 (-0.21%) Dow
39,869.38 -38.62 (-0.10%) Nasdaq
16,698.32 -44.07 (-0.26%) Bitcoin USD
65,428.99 -914.06 (-1.38%) CMC Crypto 200
1,374.06 -19.98 (-1.43%)
GILD May 2024 65.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:55PM EDT. Market open.
| Previous close | 0.0300 |
| Open | 0.0200 |
| Bid | 0.0100 |
| Ask | 0.0300 |
| Strike | 65.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0100 - 0.0300 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.62k |
Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
Yahoo FinanceOne stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
© 2024 Yahoo. All rights reserved.